Benzinga | Mar 9, 2021 05:18AM EST

Rigel Pharmaceuticals Awarded U.S. Patent 10,941,135 'Nrf2 activating compounds and uses thereof'

Aspects of the present disclosure include compounds that activate Nrf2. Such compounds may find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.